目的 探讨乙肝表面抗原(hepatitis B surface antigen,HBsAg)阴性恶性肿瘤患者化疗后乙肝病毒(hepatitis B virus,HBV)再激活的相关危险因素。方法 收集2006-01至2014-12在武警上海总队医院接受化疗的HBsAg阴性恶性肿瘤患者570例。根据化疗后HBV是否出现再激活将患者分为再激活组25例及未被激活组545例,回顾性分析两组患者一般情况、化疗方案及实验室检查指标,对HBV再激活的潜在影响因素进行χ2检验及Logistic回归分析。结果 单因素分析表明两组患者在性别、乙肝表面抗体状态、e抗体状态、核心抗体状态及是否使用免疫抑制药方面差异有统计学意义(P<0.05),将其纳入多因素非条件Logistic回归分析,结果提示男性(OR=7.700,P<0.001)、乙肝表面抗体阴性(OR=0.056, P<0.001)、核心抗体阳性(OR=4.670, P<0.01)及使用免疫抑制药(OR=7.978, P<0.01)是导致化疗后HBV再激活的独立危险因素。结论 对于男性、乙肝表面抗体阴性、核心抗体阳性及使用免疫抑制药的HBsAg阴性的恶性肿瘤患者行化疗时,应密切监测HBV是否出现再激活或及早采取抗病毒治疗防止HBV再激活。
Abstract
Objective To investigate the occurrence of the related risk factor hepatitis B virus (HBV) reactivation after chemotherapy in hepatitis B surface antigen (HBsAg) negative patients with malignant carcinoma. Methods A total of five hundred and seventy HBsAg-negative patients with malignant carcinoma who received chemotherapy were recruited during the period of 2006-01 to 2014-12 in Shanghai Corps Hospital of Chinese People’s Armed Police Force. The patients were divided into reactivation group (n=25) and inactivation (n=545) group according to whether the virus was reactivated after chemotherapy. The general information, chemotherapy regimen and index of laboratory examination in both groups were analyzed retrospectively,2 test and logistic regression analysis were performed on potential influencing factors for HBV reactivation. Results The univariate analysis indicated that gender, hepatitis B surface antibody status, e antibody status, core antibody status and whether or no application of immune suppression were statistically significantly different between the two groups. The multivariate non-conditioned logistic regression analysis of these five factors indicated that male (OR=7.700, P＜0.001), hepatitis B surface antibody negative (OR=0.056, P＜0.001), E antibody positive (OR=4.670, P＜0.01) and application of immune suppression (OR=7.978, P＜0.01) were independent risk factors for HBV reactivation after chemotherapy. Conclusions For male, surface antibody negative, core antibody positive and application of immune suppression of HBsAg negative patients with malignant carcinoma, chemotherapy should closely monitor HBV whether reactivation or take early antiviral treatment to prevent HBV reactivation.
关键词
乙肝表面抗原 /
恶性肿瘤 /
化疗 /
乙肝病毒 /
再激活
Key words
hepatitis B surface antigen /
malignant carcinoma /
chemotherapy /
hepatitis B virus /
reactivation
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Chen W C, Cheng J S, Chiang P H, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy [J]. PLoS One, 2015, 10(6): e0131545.
[2] Ho E Y, Yau T, Rousseau F, et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy [J]. Hepatol Int, 2015, 9(2): 224-230.
[3] Tang W, Chen L, Zheng R, et al. Prophylactic effect of lamivudine for lhemotherapy-induced hepatitis B reactivation in breast cancer: a Meta-analysis [J]. PLoS One, 2015, 10(6): e0128673.
[4] Liu J Y, Sheng Y J, Ding X C, et al. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis [J]. J Formos Med Assoc, 2015, 114(2):164-173.
[5] Yang Y, Du Y, Luo WX, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy [J]. Cancer Chemother Pharmacol, 2015, 75(4): 783-790.
[6] Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy[J]. Int J Hematol, 2015, 101(4): 398-404.
[7] Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B - cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factor and survival [J]. Chin J Cancer, 2015, 34(1): 18.
[8] Law M F, Lai H K, Chan H N, et al. The impact of hepatitis B virus(HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma[J]. Eur J Cancer Care(Engl), 2015, 24(1): 117-124.[9] 吴盛喜,许鸿鹞,黄河澄,等.HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J].临床肝胆病杂志,2016,32(1):110-113.
[10] 杨小舟,崔铁军,解 莹,等. 核苷类药物对恶性肿瘤患者化疗后乙型肝炎病毒再激活的研究[J]. 中华医院感染学杂志,2016,26(2):289-297.
[11] Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival [J]. Chin J Cancer, 2015, 34(5): 225-234.
[12] Elbedewy T A, Elashtokhy H E, Rabee E S, et al. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening[J]. J Egypt Natl Canc Inst, 2015, 27(1): 11-18.
[13] 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会,中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J].中华血液学杂志,2013,34(11):988-993.
PDF(701 KB)
